CFO departure
Caribou Biosciences, Inc. discloses CFO departure: Sriram Ryali
Caribou Biosciences, Inc. reported in a Form 8-K filed October 6, 2026 a change involving its Chief Financial Officer, Sriram Ryali. The filing's own words are quoted below.
In the filing's words
The employment of Sriram Ryali, the Company’s Chief Financial Officer, will terminate on the date the Company executes a binding definitive agreement for a strategic alternative, and such termination would be treated as a termination “without cause” under the Employment Agreement, dated January 2, 2025, between the Company and Mr. Ryali (the “Ryali Employment Agreement”).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Caribou Biosciences, Inc. (CRBU) |
|---|---|
| Event | Departure |
| Outgoing | Sriram Ryali |
| Effective | not stated in the source |
| 8-K filed | October 6, 2026 |
| SEC CIK | 0001619856 |
Caribou Biosciences, Inc. reported this change in a Form 8-K, Item 5.02, filed October 6, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-10-07
Documented unknowns
- effective: The filing gives "the date the Company executes a binding definitive agreement for a strategic alternative", which is not a calendar date.
Something wrong about Sriram Ryali? Send a correction with the primary source.